| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Previously, we reported that we could induce tolerance dendritic cell (tDCs) which had strong immune tolerance ability with the stability in the condition of the inflammatory environment by using C kinase inhibitors (PKCI) in the maturity process of the dendritic cell of human. In addition, we made a comparison between PKCI-tDCs and tDCs derived other materials, PKCI-tDCs was shown to be superior effects than other tDCs. Also PKCI-tDCs could be derived from the peripheral blood of the patient with collagen diseases (Sjogren's syndrome and rheumatoid arthritis). From these results mentioned above, PKCI-tDCs might have useful possibility in clinical application.
|
